Rx Medicare

The European Medicines Agency has reviewed further data on the centrally authorised pandemic vaccines, Celvapan, Focetria and Pandemrix. The Agency has reaffirmed their positive balance of benefits and risks in the context of the current H1N1v influenza pandemic. The data on Focetria and Pandemrix indicate that a single dose of these vaccines is able to trigger an immune response that may be sufficient to give protection against the H1N1v pandemic influenza in some age groups.

Read More…

Related Posts

• European Medicines Agency Recommends Authorisation Of Two Vaccines For Influenza Pandemic (H1N1) 2009
• European Medicines Agency Updates On Pandemic Influenza
• Safety Monitoring Programme Up And Running For Swine Flu Vaccines
• Baxter Receives European Commission Approval For CELVAPAN H1N1 Pandemic Influenza Vaccine
• Inovio Biomedical Universal Influenza Vaccines Demonstrate 100% Protection Against Current Pandemic A/H1N1 Influenza Viruses In Animal Studies
• European Medicines Agency Recommends Withdrawal Of Dextropropoxyphene-containing Medicines
• Inviragen Researching Vaccines To Protect Against Pandemic And Seasonal Influenza Viruses
• Pandemic Flu, Like Seasonal H1N1, Shows Signs Of Resisting Tamiflu
• Virus Hybridization Could Create Pandemic Bird Flu
• Pandemic Hybrid Of Bird And Human Seasonal Flu Possible Say Scientists
• Poor Evidence For Effectiveness Of Influenza Vaccines In Elderly
• Swine Flu Pandemic Weekly Report Thursday 11 February 2010, Wales
• Pandemic Preparedness Untested In Ontario Hospitals
• Government Of Canada Announces Significant Contribution To WHO Global Pandemic Relief Efforts
• Study Investigates Who Is Most Likely To Take Precautions During A Pandemic

Tags: agency, efficacy, european, h1n1v, medicines, pandemic, reaffirms, safety, vaccines

This entry was posted on Sunday, November 22nd, 2009 at 8:11 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.